title: AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
abstract: BACKGROUND
  Previous studies have shown that patients with Bcr-Abl-positive acute lymphoblastic leukemia (ALL) either have primary disease that is refractory to imatinib mesylate or develop disease recurrence after an initial response.
  
  
  METHODS
  The authors investigated the effects of a newly designed Bcr-Abl inhibitor, AMN107, by comparing its in vitro inhibitory potency on p190 Bcr-Abl ALL cell lines with that of imatinib.
  
  
  RESULTS
  In two Philadelphia (Ph)-positive ALL cell lines, AMN107 was found to be 30-40 times more potent than imatinib in inhibiting cellular proliferation. AMN107 was also more effective than imatinib in inhibiting phosphorylation of p190 Bcr-Abl tyrosine kinase in cell lines and primary ALL cells. The inhibition of cellular proliferation was associated with the induction of apoptosis in only one of the cell lines. No activity was observed in cell lines lacking the BCR-ABL genotype.
  
  
  CONCLUSIONS
  The results of the current study suggest the superior potency of AMN107 compared with imatinib in Ph-positive ALL and support clinical trials of AMN107 in patients with Ph-positive ALL.
authors.affiliation: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA.
authors.forename: Srdan
authors.initials: S
authors.lastname: Verstovsek
authors.forename: Mirna
authors.initials: M
authors.lastname: Golemovic
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Tashi
authors.initials: T
authors.lastname: Manshouri
authors.forename: Zeev
authors.initials: Z
authors.lastname: Estrov
authors.forename: Paul
authors.initials: P
authors.lastname: Manley
authors.forename: Tong
authors.initials: T
authors.lastname: Sun
authors.forename: Ralph B
authors.initials: RB
authors.lastname: Arlinghaus
authors.forename: Leila
authors.initials: L
authors.lastname: Alland
authors.forename: Margaret
authors.initials: M
authors.lastname: Dugan
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
authors.forename: Francis
authors.initials: F
authors.lastname: Giles
authors.forename: Miloslav
authors.initials: M
authors.lastname: Beran
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001549:Benzamides; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D010766:Phosphorylation; D010879:Piperazines / Q000494:pharmacology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology; D011743:Pyrimidines / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases; C498826:nilotinib